1 2	Plasma proteins identify increased number of carotid plaques and predict occurring atherosclerotic events
3	
4	Baragetti A <sup>1,2*</sup> , Grigore L <sup>2</sup> , Olmastroni E <sup>1</sup> , Mattavelli E <sup>1,3</sup> , Catapano AL <sup>1,2</sup>
5	1: Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
6	2: IRCCS Multimedica Hospital, Milan, Italy
7	3: Bassini Hospital, Cinisello Balsamo, Milan, Italy
8	
9	(*) Corresponding author:
10 11 12 13 14 15 16 17 18 19 20 21 22 23	Dr. Andrea Baragetti, PhD Department of Pharmacological and Biomolecular Sciences, University of Milan, Italy IRCCS Multimedica Hospital, Milan Via Balzaretti, 9 – 20133 Milan, Italy Ph: +39 0257998779 Email: andrea.baragetti@unimi.it Keywords: Cardiovascular risk; Carotid plaques; proteomics Running title: plasma proteomics and number of carotid plaques Word count: 5,161
24	
25 26	

#### 27 Abstract

#### 28 Background

The number of carotid plaques independently predicts incident atherosclerotic cardiovasculardisease (ACVD).

However, performing vascular imaging in apparently healthy subjects is challenging, owing organizational/economical barriers. Plasma proteomics can offer an alternative approach to identify

- individuals with carotid plaques, at high risk of eventually developing ACVD.
- 34

#### 35 Methods

In this observational study, we studied by Normalized Protein eXpression (NPX; Olink<sup>TM</sup>), the plasma levels of 368 proteins in 664 subjects from the PLIC study, who were screened by ultrasound for the presence of carotid plaques. We clustered, by artificial intelligence, the proteins that more accurately identified subjects, stratifying them according to the number of plaques they

40 presented with. We also study prediction of occurring events over 22 years.

#### 41 **Results**

42 299/664 subjects had at least 1 carotid plaque. Among those, 77 subjects presented with only one

43 plaque, 101 with 2 plaques and 121 with  $\geq$ 3 plaques (3+). The remaining 365 subjects with no

- 44 plaques acted as controls. The proteins differently expressed versus controls increased as a function 45 of the number of plaques. 32 proteins were shared among the groups of subjects with plaques, but
- 45 of the number of plaques, 52 proteins were shared allong the groups of subjects with plaques, but 46 87, significantly associated with the presence of 3+ plaques, improved the AUC of the ROC,
- together with the ACVD risk factors, to discriminate subjects with 3+ plaques versus the AUC of
- the ROC considering the ACVD risk factors only (AUC= 0.918 (0.887-0.943) vs AUC= 0.760
- 49 (0.716-0.801) respectively, p<0.001). The ACVD risk factors barely predicted the 198 occurring
- 50 events (AUC= 0.559 (0.521-0.598)), but proteomics associated with plaques improved the
- 51 prediction (AUC= 0.739 (0.704-0.773), p<0.001).
- 52 By analyzing the biological processes, we identified that chemotaxis/migration of leukocytes and 53 the signaling of interleukins/cytokines were the top pathways involved.
- 54

## 55 **Conclusions**

Figure 56 Plasma proteomics helps to identify apparently healthy subjects with higher number of carotid 57 plaques more accurately and to predict occurring ACVDs in those individuals.

58

#### Introduction 59

Atherosclerotic Cardiovascular Disease (ACVD) is the leading cause of death worldwide<sup>1</sup>. In 60 61 "apparently healthy" population a subset of subjects with subclinical ACVD can be detected and these subjects are identified as high, or very high, risk in contemporary cardiovascular guidelines, 62 and carotid plaques have been suggested as a hallmark of increased ACVD risk <sup>2-4</sup>.

63

However, applying noninvasive vascular imaging procedures to detect subclinical ACVD, such as 64 those identifying carotid plaques, is challenging in "apparently healthy" population, owing 65 organizational, economical barriers, and given the substantial shortcomings in sensitivity and inter-66 operator variability <sup>5,6</sup>. 67

Plasma biomarkers have been recently used to identify people at high risk of developing<sup>7</sup> or 68 reoccurring cardiovascular events<sup>8</sup> and accumulating evidence indicates that plasma proteins, or 69 70 specific subsets of them, outperform the currently available algorithms to predict increased ACVD risk in "apparently healthy" individuals<sup>7</sup>. Yet evidence regarding their ability to inform the presence 71 of vascular plaques is still limited, as in few studies the number of plasma proteins that have been 72

investigated is limited to 86<sup>9,10</sup>. 73

Inflammation is known to play an important role in the onset and progression of plaques<sup>11</sup>. We 74 therefore sought to address the question whether we could more accurately identify "apparently 75 76 healthy individuals" carrying asymptomatic carotid plaques among 664 subjects from a free-living population of the northern area of Milan. To this end we studied, by Normalized Protein eXpression 77 (NPX) (an index of relative abundance<sup>12</sup>), the plasma levels of 368 proteins from the targeted 78 Cardio-metabolic, Inflammation, Cardiovascular II, and III panels (Olink<sup>TM</sup>). New omics techniques can inform on vascular activation of pathway related to atherosclerosis<sup>13–15</sup> and the power of 79 80 proteomics as an independent marker of carotid atherosclerosis has been still proposed, albeit in a 81 limited number of subjects and by addressing a maximum of 82 plasma proteins linked to 82 cardiovascular disease <sup>16,17</sup>. Therefore, we searched for proteins whose expressions in plasma, 83 recapitulating biologically relevant pathways, can improve the accuracy to identify apparently 84 healthy subjects with asymptomatic atherosclerotic disease at the carotids and if they also could 85 predict the occurrence of clinically overt atherosclerotic stages. 86

87 88

#### Materials and methods 89

#### 90 **Study population**

The population was from a subgroup of subjects from the northern area of Milan, randomly selected 91 during the basal clinical evaluation of the Progressione delle Lesioni Intimali Carotidee ("PLIC") 92 Study, which initially included 2.606 participants from 2001 to 2003 <sup>18,19</sup>. Targeted plasma 93 proteomics was available for 702 participants, but only 664 subjects, who did not develop ACVD 94 before the collection of plasma, were considered for the purpose of the study (Supplemental 95 Figure 1). Out of them, 365 were free of carotid plaques detected by ultrasound and acted as 96 97 controls. The subjects' characteristics agreed with the Sex and Gender Equity in Research (SAGER) guidelines <sup>20</sup>. The PLIC Study has been approved by the Ethics Committee of the University of 98 Milan (SEFAP/Pr.0003). Written informed consent was obtained from subjects (all over 18 years-99 old), in accordance with the Declaration of Helsinki. This work is an observational study and it was 100 conducted following the standards of the STrengthening the Reporting of OBservational studies in 101 Epidemiology (STROBE) initiative $^{21}$ . 102

#### Clinical and biochemical data 103

Participants in this study were screened at the Center for the Study of Atherosclerosis at E. Bassini 104 105 Hospital (Cinisello Balsamo, Milan, Italy) for the personal, familial, pathological, and

pharmacological clinical history. Subjects with malignancies (any type), chronic liver disease (selfreported or clinically documented in the records of the Hospital), chronic kidney disease
(Glomerular Filtration Rate, GFR < 60 ml/min or documented albuminuria > 30 mg/g) and pregnant
women were excluded from the study.

Information about lifestyle habits (physical activity, former or active smoking habit) was also 110 collected by validated questionnaire used in the PLIC Study as described elsewhere<sup>22</sup>. Systolic and 111 diastolic blood pressure, body mass index (BMI), waist and hip circumferences were measured. We 112 followed the recent EAS/ESC guidelines for the diagnosis of hypertension, for the diagnosis of 113 dyslipidemia and for the definition of the cut-off of waist circumference (>94 cm for men and >88 114 cm for women)<sup>23</sup>. Blood samples were collected from antecubital vein after 12 hours fasting on 115 NaEDTA tubes (BD Vacuette), centrifuged at 3,000 rpm for 12 minutes (Eppendorf 580r, 116 Eppendorf, Hamburg, Germany) aliquoted in multiple 200 ul samples, stored at -80 degrees for the 117 subsequent profiling of biochemical parameters (which included: total cholesterol, High-Density 118 Lipoprotein cholesterol (HDL-C), triglycerides, ApoB, ApoA-I, glucose, Lp(a), and C-Reactive 119 120 Protein (CRP)). All the measurements were performed on the aliquots, thawed for the first time, using immuno-turbidimetric and enzymatic methods thorough automatic analyzers (Randox, 121 122 Crumlin, UK). Low-Density Lipoprotein cholesterol (LDL-C) was derived from Friedewald formula. Lipoprotein(a) (Lp(a)) was measured by immunoassay (Randox, Crumlin, UK). 123

124

#### 125 Carotid ultrasound

126 Carotid ultrasound analysis was performed by a single expert sonographer, blinded on subject's 127 identity and clinical history, with a linear ultrasound probe (4.0e13.0 MHz frequency, 14X48 mm 128 footprint, 38 mm field of view, Vivid S5 GE Healthcare®, Wauwatosa, WI, USA). A detailed 129 description of the ultrasound methodology, based on validated protocol for the PLIC study, has 130 been published elsewhere<sup>19</sup>.

Carotid plaques were defined if (i) focal loci were identified and/or (ii) if the measured carotid
Intima Media Thickness (IMT) was equal or above than1.3 mm in any vascular tract (common,
bulb, bifurcation, internal and external tracts) of one or both carotid arteries <sup>24</sup>.

134

#### 135 Plasma proteomics

368 proteins were measured in plasma by Proximity Extension Assay (PEA) technology. The 136 proteins are included in the Cardiovascular II, Cardiovascular III, Inflammation and Cardio-137 metabolic panels of Olink<sup>TM</sup> platform. The complete list of the proteins that are included in the 138 panels, their Uniprot ID and the Olink ID, are provided by the company (http://www.olink.com). 139 Proteins were measured from 200 uL of plasma samples by Proximity Extension Assay (PEA). 140 Plasma samples from each subject was separated from whole blood by centrifugation (3,000 rpm, 141 12 minutes at 4 degrees), aliquoted in 96-wells plates during the first clinical evaluation of each 142 subject (between 1998 and 2000) and immediately stored at -80 degrees up to 2018, when they were 143 sent to Olink<sup>TM</sup> (Uppsala, Sweden) for proteomic characterization <sup>7</sup>. The final assay read-out of 144 each determination is given in Normalized Protein eXpression (NPX), which is an arbitrary unit on 145 log2-scale where a high value corresponds to a higher protein plasma level. Each PEA measurement 146 has a lower detection limit (LOD) calculated versus negative controls that are included in each run, 147 and measurements of individual proteins below LOD for each panel were removed from further 148 analysis (2 samples from Cardiometabolic panel, 29 samples from Cardiovascular II; 31 samples 149 from the Inflammation panel; all the samples were with measurement>LOD in the Cardiovascular 150 151 III panel). All assay characteristics including detection limits, the measurements of assay

performance, and validations are available from the manufacturer webpage (http://www.olink.com).
All raw data can be provided upon reasonable written request to ALC.

#### 154 Statistical analysis

#### 155 *Descriptive statistics*

Clinical and biochemical data are presented as median with interquartile ranges (the lower 25th 156 percentile and the upper 75th percentile). After checking for the type of distribution of linear 157 variables (Shapiro-Wilk Test), we compared them between either two groups (Kolmogorov-158 159 Smirnov test) or four groups (controls, subjects with 3+, with 2 and with 1 carotid plaque), either by Analysis of Variances (ANOVA) and Bonferroni post-hoc analysis (if variables were normally 160 distributed variables), or by Kruskal-Wallis test (if non-normally distributed variables). 161 Dichotomous variables were compared by Fisher's chi-square test. Grubb's test for the detection of 162 the outliers was performed for all the linear variables before running tests. P values less than 0.05 163 were considered significant for all the statistical analyses. SPSS<sup>TM</sup> v.24 for Windows (IBM 164 corporation®) was used for all statistical analyses. Graphs were prepared using Graphpad® (v.9.0) 165 and Excel (Microsoft®). 166

167

#### 168 <u>Machine Learning model</u>

Proteomics data were analyzed by Machine Learning (ML) model, previously published for
 proteomics data in PLIC cohort<sup>25</sup>.

In brief, the ML model consists of an eight binary outcome gradient boosting prediction model 171 172 (XGboost), including the 368 proteins measured in the cohort. The XGboost model is a statistical learning technique, which produces a non-linear model in the form of an ensemble of weak 173 prediction tree-based models. The extreme gradient boosting classification algorithm optimizes a 174 cost function<sup>26</sup> by iteratively choosing a weak hypothesis that points in the negative gradient 175 direction. Using a fivefold cross-validation by random reshuffling of the training set, overfitting 176 was avoided. The XGBoost classifier model was trained in the derivation cohort with 1000 iteration 177 round and 0.300 learning rate. Hyperparameter optimization was performed by k-fold iteration. To 178 avoid overfitting of the models, the dataset was randomly split into a training set (70% of total 179 sample; "train set") and the algorithm was thereafter applied to the internal validation set (30% of 180 total sample; "test set"). We applied a permutation (randomization test) to evaluate statistical 181 validity of the results, since standard univariate significance tests cannot be applied to the used 182 183 models due to the large number of tests. By evaluating the distribution of all the results obtained in these simulations and comparing it to the true outcomes, we computed statistical significance 184 185 associated with the joint panel of the selected markers. We also reported importance scores for each of the proteins that demonstrate preferences of model when constructing non-linear prediction 186 187 function based on the selected biomarkers. (Random Forest classifiers). Sensitivity and specificity to predict the outcome, were performed by running analysis of Receiver Operating Curves (ROC). 188 189 Comparison of AUC was performed according to the method of Hanley-McNeil. All the ML models were constructed by using Python 6.4.5 with pandas, scikit-learn, NumPy, XGboost. 190

191

#### 192 *Gene Ontology (GO) and KEGG pathway enrichment analyses*

We conducted enrichment analysis of biological processes with the proteins that emerged as significantly associated with carotid atherosclerosis following in silico strategies, as previously published <sup>27,28</sup>. The DAVID (The Database for Annotation, Visualization, and Integrated Discovery, NIAID, North Bethesda, MD, USA) platform was used for gene ontology (GO) enrichment analyses. The significant GO biological processes (GO\_bp) were selected for

Pvalue<0.05. Then, for each GO biological process (GO\_bp) we annotated the fold of enrichment, an index of the percentage of proteins belonging to a pathway, and the false discovery rate (FDR) to indicate how likely the enrichment is by chance (FDR<0.05 indicates a statistically significant enrichment of proteins in that pathway).

202

#### 203 **Results**

#### 204 Increased number of plasma proteins associate with a higher number of carotid plaques.

205

Out of 664 apparently healthy subjects, 299 presented with at least one plaque in one of the 206 carotids, while 365 did not present any plaque and acted as "controls" (the clinical and biochemical 207 parameters are reported in **Supplemental Table 1**). Out of the 299 subjects presenting at least one 208 plaque, 77 had one, 101 subjects had 2 and 121 subjects presented with 3 or more plaques (by 3 up 209 to 7 plaques as a maximum; herein defined as "3+"; the ultrasonographic results are reported in 210 Supplemental Table 2). The analysis of the prevalence of the main ACVD risk factors showed a 211 significant trend for active smoking, hypertension, dyslipidemia, increased waist circumference and 212 213 reduced physically activity associated with an increased number of plaques (Supplemental Table 3). Of note, the plasma levels of a widely used marker of chronic low-grade inflammation, CRP, did 214 not differ among all the groups (P<sub>trend</sub>=0.427 Supplemental Table 3), while the number of plasma 215 proteins with significantly different NPX increased as a function of the number of plaques vs 216 217 controls. In fact, 17 proteins were significantly different in subjects with 1 carotid plaque compared 218 to controls (1 reduced and 16 increased; Figure 1A, Supplemental Table 4A), 47 proteins were differently expressed in the plasma of the subjects with 2 plaques (4 proteins reduced and 43 219 increased; Figure 1B, Supplemental Table 4B) and 97 proteins were differently expressed in 220 221 subjects with 3+ plaques versus controls (9 reduced and 88 increased; Figure 1C, Supplemental Table 4C). 222

Overall, 32 shared proteins were differently expressed among subjects with increasing number of plaques versus controls. Indeed, 6 proteins, increased in subjects with 1 plaque, were also higher in subjects with 2 and in those with 3+ plaques versus controls, the NPX of 2 additional proteins were also higher in subjects with 3+ plaques only (**Table 1**) and, finally, 24 proteins, 2 reduced and 22 increased in subjects with 2 plaques, were present also in subjects with 3+ plaques (**Table 1**).

- 228
- 229

#### The shared proteins associated with increasing number of plaques recapitulate biological pathways related with atherosclerosis.

232

We analyzed whether the plasmatic expressions of the 32 shared proteins recapitulate biological 233 pathways associated with the development of carotid atherosclerosis. To this end, we performed a 234 protein-protein network (STRING v.11<sup>29</sup>) and gene ontology (GO) enrichment analyses (see 235 methods). By interrogating in silico dataset, we predicted that almost all the 32 proteins could be 236 linked into a network of possible biologically relevant pathways, with Interleukin-6 (IL6), Matrix-237 Metalloproteinase-9, Interleukin-18 (IL18) and plasminogen activator inhibitor 1 (SERPINE1) 238 being central connectors (Figure 2A). We then deciphered this complex scenario by gene ontology 239 (GO) enrichment analysis and, although up to 51 representative biological processes were annotated 240 ("GO bp" in Supplemental Table 5), only 9 of them were principally represented by most of the 241 32 proteins with a significant probability (FDR< 0.05; the fold of enrichment for each GO bp is 242 243 reported in **Supplemental Table 5**). These GO bp included pathways biologically relevant for the development of atherosclerosis, such as "proteolysis", "immune response", "cytokine-mediated 244 signaling pathway", "signal transduction", "cell-cell signaling", "positive regulation of 245

inflammatory response", "chemotaxis" and "defense response to Gram positive bacteria" (Figure 28).

248

#### A higher number of biological pathways associates with the presence of a higher number of carotid plaques.

We also sought to investigate whether the additional proteins that were not shared among the groups of subjects with increasing number of plaques, inform on non-redundant biologically relevant pathways.

Indeed, 9 proteins (out of the 17) were differently expressed only in subjects with 1 plaque;
Supplemental Table 4A), 17 (out of the 47) only in subjects with 2 plaques; Supplemental Table 4B) and 65 (out of the 97) only in subjects with 3+ plaques (Supplemental Table 4C).

- 257 We found 5 GO\_bp that, out of 13 annotated, barely represented the presence of one carotid plaque
- only compared to controls ( $-log_{10}p$ -value $\geq 1.3$ ; **Supplemental Table 6A**) and included "viral entry into host cells" and other T-cell mediated pathways (**Figure 3A**). By contrast, the number of
- GO bp significantly associated with the presence of 2 plaques only increased up to 22 (out of 35
- annotated; **Figure 3B**), with only one of them being also found to be associated with the presence of
- 1 plaque ("positive regulation of NF-kappaB transcription factor activity"; in Supplemental Table
   6B).
- 264 Finally, we found that the number of GO bp significantly associated with the presence of  $3^+$ plaques markedly increased up to 80 (out of 104 annotated; Figure 3C). It is of note that only 6 of 265 266 them were also found among the pathways associated with the presence of one plaque only ("response to hypoxia", "positive regulation of protein phosphorylation", "signal transduction", "T 267 cell co-stimulation", "positive regulation of peptidyl-serine phosphorylation", "viral entry into host 268 cell") and 16 were also found among the pathways associated with the presence of 2 plaques 269 (including pathways involved in leukocytes chemotaxis, migration, cell adhesion, inflammatory 270 response, immune response, and other more specific, such as "positive regulation of MAP kinase 271 activity", "positive regulation of protein kinase B signaling", "response to lipopolysaccharide", 272
- "defense response to Gram- bacterium" and "antimicrobial humoral immune response mediated by
  antimicrobial peptide") (Supplemental Table 6C).

This observation indicates that, especially in the presence of 3+ plaques, an increased number of proteins is linked to a larger number of pathways involved in the development of atherosclerosis.

277

## 278 Plasma proteins improve the accuracy of predicting the number of carotid plaques.

279

We looked for the performance of plasma proteomics to improve the capability of the classical
ACVD risk factors to distinguish the apparently healthy subjects who are still exposed to carotid
atherosclerosis.

Only the 97 proteins that were differently expressed in subjects with 3+ plaques versus controls contributed to an improvement of the ROC (AUC= 0.683 (0.601-0.785), p<0.001) (**Table 2**), while neither the 17 proteins that were differently expressed in subjects with only one plaque, nor the 47 differently expressed in subjects with 2 plaques, exerted this performance (AUC=0.504 (0.461-0.501) r=0.048 and AUC= 0.580 (0.502 0.671) r=0.082 respectively (Table 1))

287 0.591), p=0.948 and AUC= 0.589 (0.503-0.671), p=0.083, respectively (**Table 1**)).

Next, to find the proteins, out of the 97, whose expression in plasma can significantly improve the accuracy to identify subjects with higher number of carotid plaques on top of the factors commonly considered for the assessment of ACVD risk, we harnessed machine learning model which listed 87 important contributors for a significantly increased performance of the ROC curve. Of note, these 87 proteins improved the accuracy of the classical ACVD risk factors (hypertension, active smoking habit, increased waist circumference, dyslipidemia and reduced physical activity) to identify the subjects with 3+ plaques from controls (**Supplemental Table 7** lists the proteins by descending

- 295 importance factor derived from random forest classifier and their mean NPX (±standard error),
- being reduced for 5 and increased for 82 proteins in subjects with 3+ plaques vs controls). Indeed,

the AUC of the model including these 87 proteins together with the risk factors was markedly superior to the AUC of the model including the same ACVD risk factors alone (AUC= 0.918(0.887-0.943) vs AUC= 0.760 (0.716-0.801) respectively, p<0.001; Figure 4A).

These findings support the concept that plasma proteomics independently predict the presence of a higher number of carotid plaques and improves our capability to identify apparently healthy subjects with diffuse carotid atherosclerosis (three or more plaques).

303

# Plasma proteins associated with number of carotid plaques also predict occurring ACVDs. 305

Finally, to study whether the proteins that identify subjects with carotid plaques, and that recapitulate biologically relevant pathways in plasma, could also improve the performance of the commonly used risk factors to predict occurring ACVDs, we followed the population over 22 (21-23) years.

- 198 events occurred over time (29.81% in the population). Overall, ACVD classical risk factors
- 311 modestly predicted the occurrence of the events (AUC= 0.559 (0.521-0.598)) and were not
- prevalent among subjects with an incurring event. By contrast, 87 proteins that were associated with
- the presence of 3+ plaques (including also the 32 shared proteins) markedly improved the ROC to
- predict the event vs the ROC of the model with the same classical risk factors only (AUC=0.739 (0.704-0.773), p<0.001; Figure 4B)).
- 316 Of note, the AUC of the ROC considering the 32 shared proteins only was also significantly higher
- vs the ROC considering the ACVD risk factors only (p=0.001), although its performance was
- attenuated (AUC= 0.660 (0.623-0.696); Figure 4C).
- 319

## 320 Discussion

In this study we searched for proteins, out of a set of 368 measured in plasma by PEA technology, whose expressions can recapitulate biologically relevant pathways and can also improve the accuracy to identify apparently healthy subjects presenting with carotid plaques and to predict occurring ACVDs.

We detected proteins whose plasmatic expression significantly discriminates subjects who, although 325 being apparently healthy according to the analysis of the classical ACVD risk factors, present with 326 327 carotid atherosclerosis versus subjects who do not display atherosclerosis and that, in our study, were considered as "controls". Moreover, we found that the significance of this association 328 increased as a function of the number of carotid plaques analyzed by ultrasound, and we also 329 provide a specific set of proteins that were associated with diffuse atherosclerosis (3+ plaques). 330 331 Indeed, we identified 87 proteins, which associated with the presence of three or more plaques, presenting either a reduced (5) or increased (82) plasmatic expression compared to controls. By 332 contrast, plasma proteomics was not able to significantly discriminate neither the subjects 333 334 presenting with 2 or with just one carotid plaque. The finding that proteomics did not discriminate 335 the subjects with lower number of plaques could perhaps be due to the smaller number of subjects in these groups. Anyhow, we cannot rule out the effect of the clinical conditions that mostly 336 contribute to hemorheological turbulence and endothelial damage, such as hypertension and 337 smoking habit, increased waist circumference, dyslipidemia and reduced physical activity, which 338 were prevalent in subjects with 3+ plaques but not in the subjects with 2 or with 1 plaque only 339 340 versus controls and which were also associated with higher NPX values for the majority of proteins analyzed (Supplemental Figure 2A-E). 341

342 The AUC of the model combining the information of these 87 proteins with that of the classical

343 ACVD risk factors to discriminate subjects with 3+ plaques compared to controls was markedly

- 344 elevated versus the AUC of the model considering the risk factors alone. Also, this significant
- improvement held true between a subset of the two groups, matched for prevalence of hypertension,
- 346 active smoking habit, dyslipidemia, frequency of physical activity and similar waist circumference

347 (AUC= 0.840 (0.771-0.895) of the model with proteins and ACVD risk factors vs AUC= 0.684 348 (0.602-0.757) with ACVD risk factors alone, p<0.001; not shown). Therefore, this observation 349 further supports that plasma proteomics can improve our capability to classify, with higher 350 accuracy, individuals among the apparently healthy population towards higher degrees of ACVD 351 risk. Anyhow, we acknowledge that larger and independent studies are needed to validate this 352 hypothesis.

We also reported comparable levels of CRP, a commonly considered marker of low grade inflammation in clinics, in subjects with 3+ plaques versus controls. We do not rule out the relevance of CRP, which is generally elevated in subjects at higher ACVD risk and co-morbid patients, but we are more likely to support the possibility that pre-clinical inflammation in "apparently healthy" individuals could be recaptured more significantly by alternative sets of proteins in plasma.

Furthermore, by combining a high-sensitive gradient boosting machine learning strategy together with the analysis of pathways, we also provided a biological association for the large number of proteins that were predicted to be linked to the number of carotid plaques. For instance, Growth Differentiation Factor 15 (GDF-15), whose NPX was increased in subjects with 3+ plaques versus controls, ranged first out of the 87 proteins in the random forest classifier (**Supplemental Table 7**), confirming independent epidemiological studies that previously associated its increased plasma levels to ACVD risk <sup>8,30</sup>, to carotid atherosclerosis, increased carotid IMT <sup>7,9,10</sup> and high-risk

- coronary plaques defined by computed tomography angiography<sup>31</sup>. However, our additional GO analysis found that alternative set of proteins, including the spectrum of β-chemokines and other interleukins/cytokines, but not GDF-15, significantly clustered into biological pathways involved in the development of atherosclerotic process (**Supplemental Table 5** and **Supplemental table 6C**).
- From a translational point of view, these findings outline further mechanisms, involving immune cells chemotaxis in atherosclerotic lesions<sup>32</sup> and lymphocytes activation in the atheroma<sup>33</sup>, taking place yet during the subclinical stages of atherosclerosis.

Finally, the robustness of our predictions is also supported by our follow-up analysis. Indeed, the 87 proteins (including the 32 shared proteins), identifying subjects with higher number of plaques, significantly predicted incident ACVDs over a large twenty-years follow-up. From a clinical standpoint, the finding that proteomics also markedly outperformed the accuracy of ACVD risk factors, further supports the possibility to overcome, by identifying individual proteomic fingerprints, the clinical algorithms which often underestimate the residual risk in apparently healthy subjects, owing a ten-year perspective for most of them.

- 380 Our study has some limitations, and some technical aspects of our work should be discussed.
- First, our machine learning model, although previously demonstrated to provide superior accuracy compared to common statistical tools <sup>25</sup>, was trained and applied in internal sets of our population and, consequently, our findings need to be validated in independent cohorts.

Second, the methodological assessment of our proteomics analysis, although providing an optimal sensitivity to target low proteins abundancy in plasma, otherwise not reachable by common techniques of molecular biology<sup>34</sup>, relies on PCR-based amplification reactions with antibodieslinked oligonucleotides. A quantitative validation of our results will add further strength; However,

- for some of the proteins we have identified, a validation by immunoassays has been provided<sup>34</sup>. All
- in all, compared existing literature using this strategy <sup>9,10,16</sup>, we have provided information from one
  of the largest panels so far reported.
- 391 In conclusion, we found plasma proteins that, informing on pathways that are biologically relevant
- for the development of atherosclerosis, can identify apparently healthy subjects with higher numberof plaques and that outperform the classical ACVD risk factors to predict occurring atherosclerotic
- events.
- 395
- 396
- 397 Acknowledgments

The work of A.B and A.L.C. is supported by a grant Ricerca Corrente from the Ministry of Health to IRCCS Multimedica; PRIN 2017H5F943; ERANET ER-2017-2364981 and a grant A.L.C. RF-

- 400 2019-12370896
- 401
- 402 **Conflicts of Interest:** The authors declare no Conflicts of Interest relevant to the submitted work.
- 403
- 404
- 405 Figures and Tables Legends

406

#### Figure 1. Variations of plasma proteomics between subjects with one, with 2 and with 3+ carotid plaques compared to controls.

Volcano plots showing the variation of the 368 plasma proteins in (A) subjects with 1 carotid plaque, in (B) subjects with 2 carotid plaques and (C) in subjects with 3+ plaques. All the variations are referred to controls and are calculated as fold of changes (x axis). In the y axis, the p value is reported indicating the significance of the variation.

## Figure 2. The shared proteins associated with increasing number of plaques recapitulate biological pathways involved in atherosclerosis.

(A) STRING protein-protein association network reporting the predicted connections between the
32 shared proteins associated with the number of carotid plaques. (B) Bubble plot showing the most
significant GO\_bp processes represented by the 32 shared plasma proteins. Each pathway is plotted
for its fold of enrichment and the significance in the intensity (-log 10 FDR) of the signal from
proteome analysis (see methods). Significant signals were considered for FDR<0.05.</li>

## Figure 3. A higher number of biological pathways associates with the presence of a higher number of carotid plaques.

Bubble plot showing the most significant GO\_bp processes represented by (A) the unshared proteins associated the presence of one plaque only, (B) the unshared proteins associated the presence of two plaques and (C) the unshared proteins associated the presence of 3+ plaques.

## Figure 4. The plasma proteomics outperforms the ACVD risk factors in identifying subjects with 3+ plaques and in predicting occurring atherosclerotic events.

- 427 Comparison of the accuracy (Receiver Operating Curve "ROC") of the model to discriminate: (A)
- subjects with 3+ plaques from the controls, when including the ACVD risk factors together with the
- 429 87 proteins (including the 32 shared proteins) differently expressed in subjects with 3+ plaques (red
- 430 curve) versus the accuracy of the model that included the ACVD risk factors only (blue curve); (B)
- 431 subjects with incident ACVD, when including the ACVD risk factors and the 87 proteins associated
- with carotid plaques (including the 32 shared proteins) (red curve), versus the accuracy of the model
- that included the ACVD risk factors only (blue curve); (C) subjects with incident ACVD, when
- including the ACVD risk factors and the 32 shared proteins only (red curve), versus the accuracy of
- the model that included the ACVD risk factors only (blue curve); P values are derived from Hanley-
- 436 McNeil test.
- 437 **Supplemental Figure 1.** Study design.

# Supplemental Figure 2. The plasmatic expression of several proteins associated with the ACVD risk factors.

Volcano plots showing the variation of the 368 plasma proteins in (A) subjects with hypertension compared to subjects without hypertension, in (B) active smokers versus non-active smokers, (C) in subjects with higher waist circumference versus subjects with lower waist circumference, (D) in subjects with dyslipidemia and (E) in subjects who declare to practice less physical activity versus subjects who declared to practice more physical activity. All the variations are referred to controls and are calculated as fold of changes (x axis). In the y axis, the p value is reported indicating the significance of the variation.

447

#### Table 1. Shared proteins found significantly associated among the subjects with one, two or with 3+ carotid plaques compared to controls.

List of proteins with their name, their Uniprot-ID and their fold change in (A) subjects with one plaque only, in (B) subjects with two plaques and (C) in subjects with 3+ plaques. All the fold changes are referred compared to controls. Proteins that are shared between subjects with 2 and subjects with 3+ plaques only are underlined.

454

## Table 2. Targeted plasma proteomics outperforms the identification of carotids with higher number of plaques.

Table reporting the parameters of the Receiving Operating Curves (ROC) for the models including the proteins differently expressed either in subjects with one plaque only, or in subjects with 2 or in subjects with 3+ plaques compared to controls. The mean Areas Under the Curve (AUC), the 95% confidence intervals (C.I.), the z-statistics and the p-value for each ROC are reported.

461

## 462 **References**

Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The Global Burden of Cardiovascular
 Diseases and Risk: A Compass for Future Health. *J Am Coll Cardiol* [Internet]. 2022 [cited 2023 Feb
 12];80:2361–2371. Available from: https://www.jacc.org/doi/10.1016/j.jacc.2022.11.005

Fernández-Friera L, Peñalvo JL, Fernández-Ortiz A, Ibañez B, López-Melgar B, Laclaustra M, Oliva B,
 Mocoroa A, Mendiguren J, De Vega VM, et al. Prevalence, Vascular Distribution, and Multiterritorial
 Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early
 Subclinical Atherosclerosis) Study. *Circulation* [Internet]. 2015 [cited 2022 Sep 14];131:2104–2113.
 Available from: https://pubmed.ncbi.nlm.nih.gov/25882487/

Ibanez B, Fernández-Ortiz A, Fernández-Friera L, García-Lunar I, Andrés V, Fuster V. Progression of
 Early Subclinical Atherosclerosis (PESA) Study: JACC Focus Seminar 7/8. *J Am Coll Cardiol* [Internet].
 2021 [cited 2022 Sep 14];78:156–179. Available from: https://pubmed.ncbi.nlm.nih.gov/34238438/

Nicolaides AN, Panayiotou AG, Griffin M, Tyllis T, Bond D, Georgiou N, Kyriacou E, Avraamides C,
 Martin RM. Arterial Ultrasound Testing to Predict Atherosclerotic Cardiovascular Events. *J Am Coll Cardiol* [Internet]. 2022;79:1969–1982. Available from: https://pubmed.ncbi.nlm.nih.gov/35589158/

477 5. McKenna MA, Bonfield MC, Robinson T. Levels of agreement in the measurements of carotid artery 478 ultrasound across a regional vascular network. Ultrasound [Internet]. 2018 [cited 2023 Apr 479 17];26:101–109. Available from: https://pubmed.ncbi.nlm.nih.gov/30013610/ 480 6. Polak JF, Pencina MJ, Herrington D, O'Leary DH. Associations of edge-detected and manual-traced 481 common carotid intima-media thickness measurements with Framingham risk factors: the multi-482 ethnic study of atherosclerosis. Stroke [Internet]. 2011 [cited 2023 Apr 17];42:1912–1916. Available 483 from: https://pubmed.ncbi.nlm.nih.gov/21546477/ 7. 484 Hoogeveen RM, Pereira JPB, Nurmohamed NS, Zampoleri V, Bom MJ, Baragetti A, Boekholdt SM, 485 Knaapen P, Khaw K-T, Wareham NJ, et al. Improved cardiovascular risk prediction using targeted 486 plasma proteomics in primary prevention. Eur Heart J [Internet]. 2020 [cited 2020 Sep 9];Available 487 from: https://pubmed.ncbi.nlm.nih.gov/32808014/ 488 8. Nurmohamed NS, Belo Pereira JP, Hoogeveen RM, Kroon J, Kraaijenhof JM, Waissi F, Timmerman N, 489 Bom MJ, Hoefer IE, Knaapen P, et al. Targeted proteomics improves cardiovascular risk prediction in 490 secondary prevention. Eur Heart J [Internet]. 2022 [cited 2022 Feb 15]; Available from: 491 https://pubmed.ncbi.nlm.nih.gov/35139537/ 492 9. Lind L, Gigante B, Borne Y, Mälarstig A, Sundström J, Ärnlöv J, Ingelsson E, Baldassarre D, Tremoli E, 493 Veglia F, et al. The plasma protein profile and cardiovascular risk differ between intima-media 494 thickness of the common carotid artery and the bulb: A meta-analysis and a longitudinal evaluation. Atherosclerosis [Internet]. 2020 [cited 2023 Apr 17];295:25–30. Available from: 495 496 https://pubmed.ncbi.nlm.nih.gov/31981948/ 497 10. Lind L, Gigante B, Borné Y, Feldreich T, Leppert J, Hedberg P, Ostgren CJ, Nystrom FH, Sundstrom J, 498 Arnlov J, et al. Plasma Protein Profile of Carotid Artery Atherosclerosis and Atherosclerotic 499 Outcomes: Meta-Analyses and Mendelian Randomization Analyses. Arterioscler Thromb Vasc Biol [Internet]. 2021 [cited 2021 Dec 26];41:1777–1788. Available from: 500 501 https://www.ahajournals.org/doi/abs/10.1161/ATVBAHA.120.315597 502 11. Libby P. Inflammation in Atherosclerosis - No Longer a Theory. Clin Chem. 2021;67:131–142. 503 12. What is NPX? - Olink [Internet]. [cited 2022 Sep 2];Available from: https://www.olink.com/fag/what-504 is-npx/ 505 13. Joshi A, Rienks M, Theofilatos K, Mayr M. Systems biology in cardiovascular disease: a multiomics 506 approach. Nat Rev Cardiol [Internet]. 2021;18:313-330. Available from: 507 https://pubmed.ncbi.nlm.nih.gov/33340009/ 508 14. Nurmohamed NS, Kraaijenhof JM, Mayr M, Nicholls SJ, Koenig W, Catapano AL, Stroes ESG. 509 Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction. Eur Heart J 510 [Internet]. 2023;Available from: https://pubmed.ncbi.nlm.nih.gov/36988179/ 511 15. Borrelli A, Marrano N, Biondi G, Rella M, Roberto L, Cignarelli A, Perrini S, Laviola L, Giorgino F, 512 Natalicchio A, et al. Acute ischemic stroke: how to investigate the association between disease etiology and gene expression profiles: Selected Abstract – Spring Meeting 2023. European 513 514 Atherosclerosis Journal [Internet]. 2023 [cited 2023 Sep 8];2:20–20. Available from: 515 https://www.eathj.org/index.php/eaj/article/view/32 16. Sandstedt J, Vargmar K, Björkman K, Ruetschi U, Bergström G, Hultén LM, Skiöldebrand E. COMP 516 517 (Cartilage Oligomeric Matrix Protein) Neoepitope: A Novel Biomarker to Identify Symptomatic 518 Carotid Stenosis. Arterioscler Thromb Vasc Biol [Internet]. 2021;41:1218–1228. Available from: 519 https://pubmed.ncbi.nlm.nih.gov/33472398/

520 521 522	17.	Lind L, Ärnlöv J, Lindahl B, Siegbahn A, Sundström J, Ingelsson E. Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis. <i>Atherosclerosis</i> [Internet]. 2015;242:205–210. Available from: https://pubmed.ncbi.nlm.nih.gov/26204497/
523 524 525 526	18.	Olmastroni E, Baragetti A, Casula M, Grigore L, Pellegatta F, Pirillo A, Tragni E, Catapano AL. Multilevel Models to Estimate Carotid Intima-Media Thickness Curves for Individual Cardiovascular Risk Evaluation. <i>Stroke</i> [Internet]. 2019 [cited 2019 Jul 8];50:1758–1765. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31164073
527 528 529	19.	Baragetti A, Mattavelli E, Grigore L, Pellegatta F, Magni P, Catapano AL. Targeted Plasma Proteomics to Predict the Development of Carotid Plaques. <i>Stroke</i> [Internet]. 2022 [cited 2022 Sep 1];53. Available from: https://pubmed.ncbi.nlm.nih.gov/35775410/
530 531 532 533	20.	Heidari S, Babor TF, De Castro P, Tort S, Curno M. Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use. <i>Res Integr Peer Rev</i> [Internet]. 2016 [cited 2022 Dec 15];1:1–9. Available from: https://researchintegrityjournal.biomedcentral.com/articles/10.1186/s41073-016-0007-6
534 535 536 537	21.	von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>Lancet</i> [Internet]. 2007;370:1453–1457. Available from: https://pubmed.ncbi.nlm.nih.gov/18064739/
538 539 540 541	22.	Baragetti A, Severgnini M, Olmastroni E, Dioguardi C, Mattavelli E, Angius A, Rotta L, Cibella J, Caredda G, Consolandi C, et al. Gut Microbiota Functional Dysbiosis Relates to Individual Diet in Subclinical Carotid Atherosclerosis. <i>Nutrients</i> [Internet]. 2021;13:1–19. Available from: https://pubmed.ncbi.nlm.nih.gov/33494335/
542 543 544	23.	Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, Backer GG De, Delgado V, Ference BA, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188.
545 546 547 548 549	24.	Johri AM, Nambi V, Naqvi TZ, Feinstein SB, Kim ESH, Park MM, Becher H, Sillesen H. Recommendations for the Assessment of Carotid Arterial Plaque by Ultrasound for the Characterization of Atherosclerosis and Evaluation of Cardiovascular Risk: From the American Society of Echocardiography. <i>Journal of the American Society of Echocardiography</i> . 2020;33:917– 933.
550 551 552 553	25.	Unterhuber M, Kresoja KP, Rommel KP, Besler C, Baragetti A, Klöting N, Ceglarek U, Blüher M, Scholz M, Catapano AL, et al. Proteomics-Enabled Deep Learning Machine Algorithms Can Enhance Prediction of Mortality. <i>J Am Coll Cardiol</i> [Internet]. 2021 [cited 2021 Dec 26];78:1621–1631. Available from: https://pubmed.ncbi.nlm.nih.gov/34649700/
554	26.	https://www.javatpoint.com/cost-function-in-machine-learning.
555 556 557	27.	Baragetti A, Da Dalt L, Moregola A, Svecla M, Terenghi O, Mattavelli E, De Gaetano LN, Uboldi P, Catapano AL, Norata GD. Neutrophil aging exacerbates high fat diet induced metabolic alterations. <i>Metabolism</i> . 2023;144.
558 559 560	28.	Nour J, Moregola A, Svecla M, Da Dalt L, Bellini R, Neyrolles O, Fadini GP, Rombouts Y, Albiero M, Bonacina F, et al. Mannose Receptor Deficiency Impacts Bone Marrow and Circulating Immune Cells during High Fat Diet Induced Obesity. <i>Metabolites</i> . 2022;12.

Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT,
Morris JH, Bork P, et al. STRING v11: Protein-protein association networks with increased coverage,
supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res*.
2019;47:D607–D613.

- Wallentin L, Eriksson N, Olszowka M, Grammer TB, Hagström E, Held C, Kleber ME, Koenig W, März
  W, Stewart RAH, et al. Plasma proteins associated with cardiovascular death in patients with chronic
  coronary heart disease: A retrospective study. *PLoS Med* [Internet]. 2021 [cited 2023 Apr 18];18.
  Available from: https://pubmed.ncbi.nlm.nih.gov/33439866/
- Bom MJ, Levin E, Driessen RS, Danad I, Van Kuijk CC, van Rossum AC, Narula J, Min JK, Leipsic JA,
  Belo Pereira JP, et al. Predictive value of targeted proteomics for coronary plaque morphology in
  patients with suspected coronary artery disease. *EBioMedicine* [Internet]. 2019 [cited 2022 Sep
  1];39:109–117. Available from: https://pubmed.ncbi.nlm.nih.gov/30587458/
- 57332.de Jager SCA; BI, KAOKSJABM van SPJ van BTJCKJBEAL. Leukocyte-specific CCL3 deficiency inhibits574atherosclerotic lesion development by affecting neutrophil accumulation.
- Schaller TH, Batich KA, Suryadevara CM, Desai R, Sampson JH. Chemokines as adjuvants for
  immunotherapy: implications for immune activation with CCL3. Expert Rev Clin Immunol.
  2017;13:1049–1060.
- Joshi A, Rienks M, Theofilatos K, Mayr M. Systems biology in cardiovascular disease: a multiomics
  approach. *Nat Rev Cardiol* [Internet]. 2021 [cited 2021 Oct 23];18:313–330. Available from:
  https://pubmed.ncbi.nlm.nih.gov/33340009/
- 581
- 582

583

#### Table 1. Shared proteins found significantly associated among the subjects with one, two or with 3+ carotid plaques compared to controls.

586

(A)

**(B)** 

(C)

Protein	Unipr ot ID	fold change	Protein	Unipr ot ID	fold change	p valu e	Protein	Unipr ot ID	fold change	p valu e
TFDI	P1064		TNFRS	O0022			CDF15	<u>Q9998</u>		
1111	6	0,01	F10A	0	0,05	3,60	<u>GDF15</u>	<u>8</u>	<u>0,05</u>	<u>6,95</u>
APN	P1514	0.02	HAVC R1	<u>Q96D4</u> 2	0.04	3 57	<u>IL6</u>	P0523	0.10	5 68
	P2793	0,02		P0408	0,04	<u> 3,37</u>	HAVC	0.096D4	0,10	<u>,00</u>
IL1RT2	0	0,02	<u>CSTB</u>	$\frac{10100}{0}$	0,04	3,20	<u>R1</u>	$\frac{\sqrt{30D}}{2}$	0,05	5,62
TNFSF 13B	Q9Y27	0.01	<u>IL18</u>	<u>Q1411</u> 6	0.04	3 1/	PRSS8	<u>Q1665</u>	0.02	5 5 5
CPB1	P1508	0,01	IGFBP7	<u>0</u> <u>Q1627</u>	0,04	<u>3,14</u>	СЅТВ	<u><u>P0408</u></u>	0,02	<u> </u>
	6 D1509	0,03		<u>0</u>	<u>0,02</u>	2,75		$\underline{0}$	<u>0,05</u>	<u>5,31</u>
CPA1	F1308 5	0,04	<u>GDF15</u>	<u>09998</u> <u>8</u>	<u>0,03</u>	2,62	13B	5	0,02	5,10
TNFRS F10A	O0022 0	0,03	PON3	<u>Q1516</u> 6	-0,06	2,53	<u>HGF</u>	<u>P1421</u> 0	0,03	4,85
IL16	Q1400	0.04	<u>PAI</u>	<u>P0512</u> 1	0.05	2 46	CHI3L1	<u>P3622</u> 2	0.05	4 47
	5	0,04	CTSD	<u>P0733</u>	0.02	2,70	IL18	<u>Q1411</u>	0.04	4.26
			TRAP	<u>9</u> <u>P1368</u>	0,03	2,38	IGFBP7	<u>6</u> <u>Q1627</u>	<u>0,04</u>	<u>4,20</u>
				<u>6</u>	<u>0,07</u>	<u>2,18</u>		$\underline{0}$	<u>0,02</u>	<u>3,97</u>
			E E	<u>Q1511</u> 3	0.04	2.04	<b>TRAP</b>	<u>P1368</u> 6	0.09	3.69
			HGF	<u>P1421</u>	0.02	1 98	TNFRS F10A	O0022	0.04	3 25
			PRSS8	<u>Q1665</u>	0.01	1,07	PLAUR	<u>Q0340</u>	0,02	2.25
			П.6	<u>1</u> <u>P0523</u>	<u>0,01</u>	<u>1,87</u>	CTSD	<u>5</u> <u>P0733</u>	<u>0,03</u>	<u>3,25</u>
			110	<u>1</u> D4076	<u>0,06</u>	<u>1,86</u>		<u>9</u> D4076	<u>0,03</u>	3,23
			<u>PGF</u>	<u>14970</u> <u>3</u>	<u>0,01</u>	<u>1,83</u>	<u>PGF</u>	<u>14970</u> <u>3</u>	<u>0,02</u>	<u>3,11</u>
			<u>IL7R</u>	<u>P1687</u> <u>1</u>	<u>-0,09</u>	<u>1,72</u>	<u>IL7R</u>	<u>P1687</u> <u>1</u>	<u>-0,12</u>	<u>2,98</u>
			<u>CHI3L1</u>	<u>P3622</u> 2	0,03	1,70	IL1RT2	P2793 0	0,02	2,85
			CPB1	P1508	0.03	1.65	TFPI	P1064	0.01	2 72
			APN	P1514	0,00	1,00	IL16	Q1400	0,01	2,72
				4 P7855	0,02	1,63		5 P10/3	0,04	2,45
			<u>CCL20</u>	<u>17855</u>	<u>0,04</u>	<u>1,61</u>	TNFR1	<u>11945</u> <u>8</u>	<u>0,02</u>	<u>2,30</u>
			IL1RT2	P2793 0	0,01	1,61	MMP9	<u>P1478</u> <u>0</u>	<u>0,05</u>	<u>2,28</u>

1	00340			CEACA	P3199		
PLAUR	<u><u><u><u></u></u><u></u><u>5</u></u></u>	0,02	1,53	<u>M8</u>	<u>131))</u> <u>7</u>	0,06	2,22
CEACA	P3199				P1514		
<u>M8</u>	7	<u>0,05</u>	1,50	APN	4	0,02	2,16
ммро	<u>P1478</u>			CCI 16	<u>01546</u>		
<u>IVIIVII 7</u>	<u>0</u>	<u>0,04</u>	<u>1,42</u>		<u>7</u>	0,02	2,09
TNED 1	<u>P1943</u>			LOV1	<u>P7838</u>		
<u>11\[K]</u>	<u>8</u>	0,01	1,41	LUAI	<u>0</u>	0,03	2,02
II 16	Q1400			DCSKO	Q8NB		
ILIO	5	0,03	1,39	<u>rcsky</u>	<u>P7</u>	0,03	2,01
LOV1	<u>P7838</u>			DAI	P0512		
LUXI	<u>0</u>	<u>0,03</u>	1,35	<u>rai</u>	<u>1</u>	0,04	<u>1,88</u>
CCI 16	<u>01546</u>			CCI 20	P7855		
	<u>7</u>	0,02	1,34	<u>CCL20</u>	<u>6</u>	0,04	<u>1,72</u>
CDA1	P1508			CDA1	P1508		
CPAI	5	0,03	1,34	CPAI	5	0,03	1,64
DCGVO	Q8NB			CDD1	P1508		
<u>PUSK9</u>	<u>P7</u>	0,03	1,30	СГВІ	6	0,03	1,58
				PCOLC	Q1511		
				E	<u>3</u>	<u>0,05</u>	<u>1,63</u>
				DON3	Q1516		
				runs	<u>6</u>	-0,04	1,36

589Table 2. Targeted plasma proteomics outperforms the identification of carotids with higher

## 590 number of plaques.

Performance	AUC	Standard	95% C.I.	z-statistic	p-value
of the models		error	(lower-upper)		
to distinguish:					
Number of					
plaques					
1 plaque vs	0.504	0.0561	0.461-0.591	0.065	0.948
controls					
2 plaques vs	0.589	0.0513	0.503-671	1.735	0.083
controls					
3+ plaques vs	0.683	0.0471	0.601-0.785	3.892	< 0.001
controls					



Figure 1.





(B)



Figure 2.

(A) Biological pathways enriched with the proteins associated with the presence of 1 carotid plaque only



# (B) Biological pathways enriched with the proteins (B) associated with the presence of 2 carotid plaques only



(C) Biological pathways enriched with the proteins associated with the presence of 3+ carotid plaques only



Figure 3.



(B) Performance of all the proteins associated with plaques in predicting occurring ACVDs



(C)

Performance of 32 shared proteins in predicting occurring ACVDs



Figure 4.



# **Supplemental Figure 1.**



**Supplemental Figure 2.**